Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF ) Freely available
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Dada, T.
Right arrow Articles by Sharma, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dada, T.
Right arrow Articles by Sharma, V.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 14, No. 2, 288-293, February 1999
© 1999 European Society of Human Reproduction and Embryology

A comparison of three gonadotrophin-releasing hormone analogues in an in-vitro fertilization programme: a prospective randomized study

T. Dada1, O. Salha, H.S. Baillie and V. Sharma

Assisted Conception Unit, St James's University Hospital, Leeds LS9 7TF, UK

The use of gonadotrophin-releasing hormone analogues (GnRHa) has resulted in improved pregnancy rates in in-vitro fertilization (IVF) treatment cycles. Traditionally, short-acting analogues have been employed because of concerns over long-acting depot preparations causing profound suppression and luteal phase defects adversely affecting pregnancy and miscarriage rates. We randomized 60 IVF patients to receive a short-acting GnRHa, nafarelin or buserelin, or to receive a depot formulation, leuprorelin, all commenced in the early follicular phase and compared their effects on hormonal suppression and clinical outcome. We found that on day 15 of administration there was a significant difference in the suppression of oestradiol from initial concentrations, when patients on buserelin were compared with patients on nafarelin or leuprorelin (54 versus 72 and 65%; P < 0.05) and also in the number of patients satisfactorily suppressed, (80 versus 90 and 90%; P < 0.05), though there were no differences between the analogues by day 21. Similarly there was no difference in hormonal suppression during the stimulation phase or in implantation, pregnancy or miscarriage rates in comparing the three agonists. We conclude that with nafarelin and leuprorelin, stimulation with gonadotrophins may begin after 2 weeks of suppression and that long-acting GnRHa are as effective as short-acting analogues with no detrimental effects on the luteal phase.

Key words: GnRHa/hormonal suppression/IVF/pregnancy

1 To whom correspondence should be addressed


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Hum ReprodHome page
S. Bjercke, P. Fedorcsak, T. Abyholm, R. Storeng, G. Ertzeid, N. Oldereid, A. Omland, and T. Tanbo
IVF/ICSI outcome and serum LH concentration on day 1 of ovarian stimulation with recombinant FSH under pituitary suppression
Hum. Reprod., September 1, 2005; 20(9): 2441 - 2447.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
T. Dada, O. Salha, V. Allgar, and V. Sharma
Utero-ovarian blood flow characteristics of pituitary desensitization
Hum. Reprod., August 1, 2001; 16(8): 1663 - 1670.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
S.F. Yim, I.H. Lok, L.P. Cheung, C.M. Briton-Jones, T.T.Y. Chiu, and C.J. Haines
Dose-finding study for the use of long-acting gonadotrophin-releasing hormone analogues prior to ovarian stimulation for IVF
Hum. Reprod., March 1, 2001; 16(3): 492 - 494.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
A. Weissman, A. Barash, and V. Sharma
A comparison of three GnRH analogues in an IVF programme
Hum. Reprod., February 1, 2000; 15(2): 493 - 495.
[Full Text]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.